39 related articles for article (PubMed ID: 21508363)
1. MT477 acts in tumor cells as an AURKA inhibitor and strongly induces NRF-2 signaling.
Jasinski P; Zwolak P; Terai K; Vogel RI; Borja-Cacho D; Dudek AZ
Anticancer Res; 2011 Apr; 31(4):1181-7. PubMed ID: 21508363
[TBL] [Abstract][Full Text] [Related]
2. Novel Ras pathway inhibitor induces apoptosis and growth inhibition of K-ras-mutated cancer cells in vitro and in vivo.
Jasinski P; Zwolak P; Terai K; Dudek AZ
Transl Res; 2008 Nov; 152(5):203-12. PubMed ID: 19010291
[TBL] [Abstract][Full Text] [Related]
3. A novel quinoline, MT477: suppresses cell signaling through Ras molecular pathway, inhibits PKC activity, and demonstrates in vivo anti-tumor activity against human carcinoma cell lines.
Jasinski P; Welsh B; Galvez J; Land D; Zwolak P; Ghandi L; Terai K; Dudek AZ
Invest New Drugs; 2008 Jun; 26(3):223-32. PubMed ID: 17957339
[TBL] [Abstract][Full Text] [Related]
4. Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis.
Dey JH; Bianchi F; Voshol J; Bonenfant D; Oakeley EJ; Hynes NE
Cancer Res; 2010 May; 70(10):4151-62. PubMed ID: 20460524
[TBL] [Abstract][Full Text] [Related]
5. Global downstream pathway analysis reveals a dependence of oncogenic NF-E2-related factor 2 mutation on the mTOR growth signaling pathway.
Shibata T; Saito S; Kokubu A; Suzuki T; Yamamoto M; Hirohashi S
Cancer Res; 2010 Nov; 70(22):9095-105. PubMed ID: 21062981
[TBL] [Abstract][Full Text] [Related]
6. Anticancer activity of litchi fruit pericarp extract against human breast cancer in vitro and in vivo.
Wang X; Yuan S; Wang J; Lin P; Liu G; Lu Y; Zhang J; Wang W; Wei Y
Toxicol Appl Pharmacol; 2006 Sep; 215(2):168-78. PubMed ID: 16563451
[TBL] [Abstract][Full Text] [Related]
7. Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors).
Hirokawa Y; Levitzki A; Lessene G; Baell J; Xiao Y; Zhu H; Maruta H
Cancer Lett; 2007 Jan; 245(1-2):242-51. PubMed ID: 16540233
[TBL] [Abstract][Full Text] [Related]
8. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J
Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment.
Medicherla S; Li L; Ma JY; Kapoun AM; Gaspar NJ; Liu YW; Mangadu R; O'Young G; Protter AA; Schreiner GF; Wong DH; Higgins LS
Anticancer Res; 2007; 27(6B):4149-57. PubMed ID: 18229422
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness.
Gaspar NJ; Li L; Kapoun AM; Medicherla S; Reddy M; Li G; O'Young G; Quon D; Henson M; Damm DL; Muiru GT; Murphy A; Higgins LS; Chakravarty S; Wong DH
Mol Pharmacol; 2007 Jul; 72(1):152-61. PubMed ID: 17400764
[TBL] [Abstract][Full Text] [Related]
11. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
Hoeflich KP; O'Brien C; Boyd Z; Cavet G; Guerrero S; Jung K; Januario T; Savage H; Punnoose E; Truong T; Zhou W; Berry L; Murray L; Amler L; Belvin M; Friedman LS; Lackner MR
Clin Cancer Res; 2009 Jul; 15(14):4649-64. PubMed ID: 19567590
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases.
Konicek BW; Stephens JR; McNulty AM; Robichaud N; Peery RB; Dumstorf CA; Dowless MS; Iversen PW; Parsons S; Ellis KE; McCann DJ; Pelletier J; Furic L; Yingling JM; Stancato LF; Sonenberg N; Graff JR
Cancer Res; 2011 Mar; 71(5):1849-57. PubMed ID: 21233335
[TBL] [Abstract][Full Text] [Related]
13. Dietary flaxseed lignan or oil combined with tamoxifen treatment affects MCF-7 tumor growth through estrogen receptor- and growth factor-signaling pathways.
Saggar JK; Chen J; Corey P; Thompson LU
Mol Nutr Food Res; 2010 Mar; 54(3):415-25. PubMed ID: 19904759
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth.
Liu Y; Ludes-Meyers J; Zhang Y; Munoz-Medellin D; Kim HT; Lu C; Ge G; Schiff R; Hilsenbeck SG; Osborne CK; Brown PH
Oncogene; 2002 Oct; 21(50):7680-9. PubMed ID: 12400010
[TBL] [Abstract][Full Text] [Related]
15. PKC-alpha inhibitor MT477 slows tumor growth with minimal toxicity in in vivo model of non-Ras-mutated cancer via induction of apoptosis.
Jasinski P; Zwolak P; Terai K; Borja-Cacho D; Dudek AZ
Invest New Drugs; 2011 Feb; 29(1):33-40. PubMed ID: 19795097
[TBL] [Abstract][Full Text] [Related]
16. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.
Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Gschwend JE; Simmet T; Debatin KM; Fulda S
Cancer Res; 2008 Oct; 68(19):7956-65. PubMed ID: 18829553
[TBL] [Abstract][Full Text] [Related]
17. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice.
Aggarwal BB; Shishodia S; Takada Y; Banerjee S; Newman RA; Bueso-Ramos CE; Price JE
Clin Cancer Res; 2005 Oct; 11(20):7490-8. PubMed ID: 16243823
[TBL] [Abstract][Full Text] [Related]
18. Deguelin inhibits growth of breast cancer cells by modulating the expression of key members of the Wnt signaling pathway.
Murillo G; Peng X; Torres KE; Mehta RG
Cancer Prev Res (Phila); 2009 Nov; 2(11):942-50. PubMed ID: 19861542
[TBL] [Abstract][Full Text] [Related]
19. Semaphorin SEMA3F affects multiple signaling pathways in lung cancer cells.
Potiron VA; Sharma G; Nasarre P; Clarhaut JA; Augustin HG; Gemmill RM; Roche J; Drabkin HA
Cancer Res; 2007 Sep; 67(18):8708-15. PubMed ID: 17875711
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer.
Sabine VS; Sims AH; Macaskill EJ; Renshaw L; Thomas JS; Dixon JM; Bartlett JM
Breast Cancer Res Treat; 2010 Jul; 122(2):419-28. PubMed ID: 20480226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
